Cadrenal Therapeutics, Inc. (NASDAQ:CVKD – Get Free Report) was the target of a significant increase in short interest in the month of September. As of September 15th, there was short interest totalling 19,400 shares, an increase of 22.8% from the August 31st total of 15,800 shares. Approximately 3.4% of the company’s shares are sold short. Based on an average daily volume of 25,600 shares, the short-interest ratio is presently 0.8 days.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reissued a “buy” rating and set a $0.20 price target on shares of Cadrenal Therapeutics in a research report on Thursday, June 6th.
Check Out Our Latest Report on CVKD
Cadrenal Therapeutics Stock Performance
Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($2.25) earnings per share for the quarter, beating the consensus estimate of ($19.04) by $16.79. On average, analysts forecast that Cadrenal Therapeutics will post -6.72 EPS for the current year.
About Cadrenal Therapeutics
Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.
Recommended Stories
- Five stocks we like better than Cadrenal Therapeutics
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
- How to Use Stock Screeners to Find Stocks
- Up 90% and Still Running: On Holding Stock’s Remarkable Climb
- How is Compound Interest Calculated?
- Is David Tepper Right About Chinese Stocks?
Receive News & Ratings for Cadrenal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cadrenal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.